MRKMerck Sharp & Dohme LLCRunning, no new patients
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Endometrial Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 990 (planned)
- Started
- Jan 10, 2021
- Main results expected
- Nov 20, 2026
- Fully finished
- Nov 20, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence
Measured over: Up to approximately 42 months
Overall Survival (OS)
Measured over: Up to approximately 54 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04634877 · record last updated 2026-09-18 · checked 2026-11-09 15:47 UTC